Cellosaurus UM-UC-3 (CVCL_1783)

Cell line name UM-UC-3
Synonyms UMUC-3; UM-UC3; UMUC3; UC-3; University of Michigan-Urothelial Carcinoma-3
Accession CVCL_1783
Resource Identification Initiative To cite this cell line use: UM-UC-3 (RRID:CVCL_1783)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: UBC-40 urothelial bladder cancer cell line index.
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: Homozygous for a CDKN2A deletion (PubMed=9850064).
Sequence variation: TP53 p.Phe113Cys (PubMed=9850064).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ECACC; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11 (ATCC; Cosmic-CLP)
10 (ECACC; PubMed=25877200)
D13S3178
D16S5398,9
D18S5114
D21S1131
D3S135817,18
D5S81812
D7S8208,9
D8S117913
FGA20,21
Penta D13
Penta E12
TH016,9
TPOX10
vWA17
Publications

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=16469639; DOI=10.1016/S0022-5347(05)00323-X
Sabichi A.L., Keyhani A., Tanaka N., Delacerda J., Lee I.L., Zou C., Zhou J.-H., Benedict W.F., Grossman H.B.
Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression.
J. Urol. 175:1133-1137(2006)

PubMed=18812553; DOI=10.1093/jnci/djn304
Park H.-S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S., Spiess P.E., Steinberg J.R., Wang Z., Katz R.L., Dinney C.P.N., Elias K.J., Lotan Y., Naeem R.C., Baggerly K., Sen S., Grossman H.B., Czerniak B.
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
J. Natl. Cancer Inst. 100:1401-1411(2008)

PubMed=19375735; DOI=10.1016/j.juro.2009.01.108
Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.
The use of short tandem repeat profiling to characterize human bladder cancer cell lines.
J. Urol. 181:2737-2748(2009)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-1749
ECACC; 96020936
KCB; KCB 2014053YJ
Cell line databases/resources CCLE; UMUC3_URINARY_TRACT
CCRID; 3131C0001001200023
Cosmic-CLP; 724838
GDSC; 724838
IGRhCellID; UMUC3
LINCS_LDP; LCL-1721
Ontologies BTO; BTO:0003723
CLO; CLO_0009487
EFO; EFO_0006771
Biological sample resources BioSample; SAMN03471418
BioSample; SAMN03473229
Chemistry resources ChEMBL-Cells; CHEMBL3307245
ChEMBL-Targets; CHEMBL612799
Gene expression databases GEO; GSM887729
GEO; GSM888824
GEO; GSM1374978
GEO; GSM1574568
GEO; GSM1670567
Polymorphism and mutation databases Cosmic; 715827
Cosmic; 724838
Cosmic; 760478
Cosmic; 845568
Cosmic; 846273
Cosmic; 928818
Cosmic; 943744
Cosmic; 1046684
Cosmic; 1082647
Cosmic; 1285132
Cosmic; 1285995
Cosmic; 1302358
Cosmic; 1927294
Cosmic; 1938480
Cosmic; 1938700
Cosmic; 2050468
Cosmic; 2057446
Cosmic; 2212694
Cosmic; 2444238
Proteomic databases PRIDE; PXD003105